Literature DB >> 21475826

Effect of the methylenetetrahydrofolate reductase gene C677T polymorphism on C-erbB-2 methylation status and its association with cancer.

Zhonggan Jin1, Qing Lu, Danhong Ge, Ming Zong, Qinghui Zhu.   

Abstract

Methylation abnormalities of cancer-related genes are recognized to play an important role in carcinogenesis. Methylenetetrahydrofolate reductase (MTHFR) regulates DNA methylation by affecting synthesis of S-adenosylmethionine, which is a universal methyl donor for methylation reactions. MTHFR gene polymorphisms that affect enzymatic activity may be associated with DNA methylation and cancer susceptibility. In the present study, we investigated the MTHFR C677T polymorphism in 247 cancer patients and 100 healthy subjects using PCR-RFLP, as well as the methylation status of the CpG island in the promoter region of the C-erbB-2 oncogene in 247 tumor and matched adjacent tissue samples using methylation-specific PCR. The results revealed that the methylation rate of the C-erbB-2 gene was significantly lower in the tumor tissues than in the matched adjacent tissues (43.3 vs. 69.2%, P=0.000). No correlation was observed between the methylation patterns of C-erbB-2 in tumor tissues and the clinicopathological characteristics of the patients. The frequency of the MTHFR gene 677 T allele was significantly higher in cancer patients than in the healthy subjects, and the combined variant genotypes (677CT+TT) significantly increased the risk of developing cancer (OR=1.619, 95% CI 1.012-2.588, P=0.043). Among the cancer patients, the methylation rate of the C-erbB-2 gene was higher in indi-viduals with the CC genotype than in those with the CT/TT genotype (50.0 vs. 39.4%). This difference was not significant (P=0.103). However, a significant difference was found in patients with breast cancer (P=0.008). In conclusion, the C-erbB-2 promoter CpG island was hypomethylated in cancer patients, and the MTHFR 677 CT/TT genotype increased the risk of developing the disease. Moreover, in breast cancer patients, the MTHFR gene C677T polymorphism had an effect on the methylation status of the C-erbB-2 gene.

Entities:  

Year:  2009        PMID: 21475826     DOI: 10.3892/mmr_00000097

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and tumor risk: evidence from 134 case-control studies.

Authors:  Min Tang; Shang-Qian Wang; Bian-Jiang Liu; Qiang Cao; Bing-Jie Li; Peng-Chao Li; Yong-Fei Li; Chao Qin; Wei Zhang
Journal:  Mol Biol Rep       Date:  2014-04-18       Impact factor: 2.316

2.  A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in breast cancer.

Authors:  Shanliang Zhong; Zhiyuan Chen; Xinnian Yu; Wenjing Li; Jinhai Tang; Jianhua Zhao
Journal:  Mol Biol Rep       Date:  2014-06-29       Impact factor: 2.316

Review 3.  Association of MTHFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: An update meta-analysis based on 51 research studies.

Authors:  Liwa Yu; Jianqiu Chen
Journal:  Diagn Pathol       Date:  2012-12-07       Impact factor: 2.644

Review 4.  Methylenetetrahydrofolate reductase gene C677T polymorphism and breast cancer risk: Evidence for genetic susceptibility.

Authors:  Pradeep Kumar; Upendra Yadav; Vandana Rai
Journal:  Meta Gene       Date:  2015-10-01

5.  MTHFR 677C>T polymorphism and the risk of breast cancer: evidence from an original study and pooled data for 28031 cases and 31880 controls.

Authors:  Singh Pooja; Justin Carlus; Deepa Sekhar; Amirtharaj Francis; Nishi Gupta; Rituraj Konwar; Sandeep Kumar; Surender Kumar; Kumarasamy Thangaraj; Singh Rajender
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

6.  MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome.

Authors:  Sofia Fragkioudaki; Adrianos Nezos; Vassilis L Souliotis; Ilenia Chatziandreou; Angelica A Saetta; Nikolaos Drakoulis; Athanasios G Tzioufas; Michael Voulgarelis; Petros P Sfikakis; Michael Koutsilieris; Mary K Crow; Haralampos M Moutsopoulos; Clio P Mavragani
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

7.  MTHFR C677T polymorphism and breast, ovarian cancer risk: a meta-analysis of 19,260 patients and 26,364 controls.

Authors:  Lilin He; Yongxiang Shen
Journal:  Onco Targets Ther       Date:  2017-01-06       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.